Total cholesterol levels and mortality risk in nonischemic systolic heart failure.

[1]  W. Grimm,et al.  Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. , 2006, European heart journal.

[2]  H. Krumholz,et al.  Statins and Mortality Among Elderly Patients Hospitalized With Heart Failure , 2006, Circulation.

[3]  J. Staessen,et al.  Low‐Density Lipoprotein Cholesterol and Mortality in Older People , 2005, Journal of the American Geriatrics Society.

[4]  J. Cohn,et al.  C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.

[5]  D. Mozaffarian,et al.  Statin therapy is associated with lower mortality among patients with severe heart failure. , 2004, The American journal of cardiology.

[6]  N. Powe,et al.  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. , 2004, JAMA.

[7]  G. Fonarow,et al.  Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. , 2003, Journal of the American College of Cardiology.

[8]  S. Anker,et al.  The relationship between cholesterol and survival in patients with chronic heart failure. , 2003, Journal of the American College of Cardiology.

[9]  G. Fonarow,et al.  Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. , 2002, Journal of cardiac failure.

[10]  K. Yano,et al.  Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study , 2001, The Lancet.

[11]  Anita Deswal,et al.  Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.

[12]  S. Anker,et al.  Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. , 2000, International journal of cardiology.

[13]  P. Fraunberger,et al.  Serum cholesterol and mortality in patients with multiple organ failure. , 2000, Critical care medicine.

[14]  S. Anker,et al.  The endotoxin-lipoprotein hypothesis , 2000, The Lancet.

[15]  S G Thompson,et al.  Survival of patients with a new diagnosis of heart failure: a population based study , 2000, Heart.

[16]  Josef Niebauer,et al.  Endotoxin and immune activation in chronic heart failure: a prospective cohort study , 1999, The Lancet.

[17]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[18]  Elliott Dc,et al.  Low lipid concentrations in critical illness: hypocholesterolemia among trauma patients. , 1997 .

[19]  G. Fonarow,et al.  Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. , 1997, Journal of the American College of Cardiology.

[20]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[21]  A J Belanger,et al.  Epidemiology of heart failure. , 1991, American heart journal.

[22]  M. Luu,et al.  Importance of hemodynamic response to therapy in predicting survival with ejection fraction ≤ 20% secondary to ischemic or nonischemic dilated cardiomyopathy , 1990 .

[23]  H. Harris,et al.  Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. , 1990, The Journal of clinical investigation.

[24]  J Pekkanen,et al.  Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. , 1990, The New England journal of medicine.

[25]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.